Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Coronary Syndrome
100%
Endogenous Fibrinolysis
84%
ST-elevation Myocardial Infarction (STEMI)
76%
Atrial Fibrillation
75%
Thrombosis
63%
Percutaneous Coronary Intervention
63%
Fibrinolysis
53%
Bleeding Risk
51%
Dual Antiplatelet Therapy
50%
Antithrombotic Therapy
49%
Meta-analysis
47%
COVID-19
43%
Bleeding
43%
Platelet Reactivity
39%
Ticagrelor
35%
Thrombus
35%
Prothrombotic Status
34%
Global Thrombosis Test
34%
Thrombus Formation
33%
P2Y12 Inhibitors
32%
Aspirin
30%
Clinical Outcomes
27%
Thrombotic
27%
Platelet Function Tests
26%
Acute Myocardial Infarction
26%
Primary Percutaneous Coronary Intervention
26%
Rivaroxaban
26%
Myocardial Infarction
25%
Lysis Time
24%
Occlusion Time
23%
Myocardial Infarction Patients
23%
Antiplatelet Therapy
23%
High Shear
21%
Arterial Thrombosis
21%
Anticoagulation
20%
Systematic Meta-analysis
20%
Apixaban
20%
Thrombolysis
19%
Thrombotic Complications
19%
Spontaneous Reperfusion
19%
Confidence Interval
18%
Major Adverse Cardiovascular Events
18%
Intensive Care Unit
18%
Cardiovascular Risk
17%
Thromboprophylaxis
17%
Randomized Controlled Trial
17%
Clopidogrel
17%
Coagulation
17%
Thrombotic Events
17%
Platelet Thrombus
16%
Medicine and Dentistry
Thrombosis
99%
Fibrinolysis
83%
Antithrombotic
77%
Atrial Fibrillation
58%
Cardiovascular System
56%
Acute Coronary Syndrome
55%
Percutaneous Coronary Intervention
52%
Bleeding
52%
Antiplatelet
51%
Coronary Artery Disease
51%
ST Segment Elevation Myocardial Infarction
44%
Meta-Analysis
42%
Cardiovascular Disease
42%
Myocardial Infarction
41%
Anticoagulation
40%
Drug Therapy
36%
Antithrombotic Therapy
35%
COVID-19
34%
Thrombocyte Function
34%
Platelet
33%
Thrombus
33%
Platelet Reactivity
32%
Systematic Review
31%
Apoplexy
29%
Acute Heart Infarction
26%
Blood Clotting
26%
Primary Percutaneous Coronary Intervention
26%
Artery Thrombosis
23%
Biological Marker
23%
Function Test
21%
Thrombin
21%
Acetylsalicylic Acid
20%
Blood Clot Lysis
19%
Heart Rhythm
17%
Cardiology
17%
Cardiovascular Risk
17%
Intensive Care Unit
17%
Major Bleeding
17%
Blood Stasis
16%
Combination Therapy
16%
Coronary Artery
16%
Disease
15%
Thromboembolism
14%
Risk Stratification
14%
Thromboprophylaxis
14%
Prevalence
14%
Randomized Controlled Trial
13%
Antiplatelet Drug
13%
Out of Hospital Cardiac Arrest
13%
Morphine
13%
Pharmacology, Toxicology and Pharmaceutical Science
Antiplatelet
92%
Anticoagulant Agent
90%
Thrombosis
90%
Acute Coronary Syndrome
89%
ST Segment Elevation Myocardial Infarction
59%
Thrombus
52%
Cardiovascular Disease
51%
Heart Infarction
49%
Atrial Fibrillation
47%
Bleeding
46%
Coronary Artery Disease
45%
Fibrinolytic Agent
43%
Acetylsalicylic Acid
33%
Cerebrovascular Accident
30%
Ticagrelor
28%
Disease
26%
Rivaroxaban
24%
Thrombin
24%
Artery Thrombosis
24%
Biological Marker
24%
Cardiovascular Risk
22%
Clopidogrel
20%
Monotherapy
19%
Combination Therapy
18%
Prevalence
18%
Pharmacotherapy
18%
Acute Heart Infarction
17%
Morphine
15%
Heart Muscle Ischemia
14%
Antithrombocytic Agent
14%
Antithrombotic Therapy
14%
Out of Hospital Cardiac Arrest
14%
Prasugrel
13%
Randomized Controlled Trial
13%
Placebo
13%
Coronavirinae
13%
Fibrinolytic Factor
13%
Pharmacodynamics
13%
Pharmacokinetics
13%
Dabigatran
12%
Apixaban
12%
Antivitamin K
12%
C Reactive Protein
12%
Vorapaxar
12%
Purinergic P2Y12 Receptor
11%
Infarction
11%
Blood Stasis
11%
Inflammation
10%
Brain Ischemia
10%
Adverse Outcome
10%